ClinicalTrials.gg
CompletedNCT04534582Updated Jan 20, 2025

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

A Phase 1 interventional study of HLX14 and EU-Prolia® in Healthy Male Volunteers, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to male participants aged 28 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
28 Years to 65 Years
Sex
Male
01

Study summary

Part I of the study: This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess the safety, tolerability, and immunogenicity of these 2 drugs.

Part II of the study: This is a randomised, double-blind, four-arm, single-dose, subcutaneous injection, parallel-controlled study to evaluate the PK, PD, safety, tolerability, and immunogenicity between-group following a single subcutaneous injection of HLX14 or US, EU, CN-sourced Prolia®.

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged> 28 and ≤ 65 years;
  2. Body weight ≥ 50 kg, (BMI) = body weight (kg)/body height2 (m2), BMI ≥ 19 and ≤ 26 kg/m2;
  3. With no disease history, or with abnormal prior medical history which has no effect on the trial as judged by the physician;
  4. Normal or abnormal without clinical significance in physical examination, vital signs, , chest imaging, clinical laboratory test, etc.;
  5. Before the trial, sign the form (ICF) and have a full understanding of trial content, process, and possible adverse events (AEs); be able to complete the study as per protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. With a history of allergy to study drugs, calcium, and/or vitamin D, or with a history of allergy to drugs or others not suitable for participating in this study as judged by the investigators;
  2. With the following diseases (including but not limited to digestive system, kidney diseases, liver diseases, nervous diseases, blood system, endocrine system, tumor, respiratory system, immune diseases, mental diseases, cardiovascular and cerebrovascular diseases, or any condition that may affect bone metabolism);
  3. With a history of upper respiratory tract infection and other acute infections within 2 weeks prior to screening;
  4. Occurred or suffering from osteomyelitis or ONJ (Osteonecrosis of the jaw) previously.

    The dental or jaw disease that is active, requiring oral surgery; or dental or oral surgery wounds have not healed; or planned for invasive dental surgery during the study.

  5. Occurrence of fracture or bone-related surgery within 6 months prior to screening;
  6. With rash, scar, tattoo, etc. at administration site that may affect drug absorption;
  7. Blood donation or massive blood loss (> 450 mL) within 3 months prior to screening;
  8. Use of any prescription drugs, over-the-counter (OTC) drugs, vitamin products, or traditional Chinese medicines within 28 days prior to screening;
  9. Participation in any drug clinical trials and use of any /comparator drugs within 3 months prior to screening;
  10. Administration of the following drugs affecting bone metabolism:

    1. Administration history of denosumab or its biosimilar products, romosozumab or its biosimilar products, cathepsin K inhibitors, diphosphonates, fluorides, or stronitum;
    2. Administration of the following within 12 months before screening: parathyroid hormone or its derivatives, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERM), tibolone, anabolic steroids, testosterone, androgen, and gonadotropin-releasing hormone agonists (GnRH-a);
    3. Administration of any prescription drug or OTC drug within 6 months or 10 half-lives of drug elimination (whichever is the longer) before screening that may have impact on the objectives of the study at the discretion of the investigator, including but not limited to heparin, warfarin, anticonvulsants (excluding benzodiazepine), systemic ketoconazole, adrenocorticotropic hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors (PI), methotrexate (MTX), calcitonin, calcitriol, diuretics, and for oral administration or injection (daily administration of ≥ 5 mg prednisone or equivalent drugs for more than 10 days);
  11. Use of any biological products (excluding vaccine) or monoclonal antibodies within 6 months prior to screening;
  12. Vaccination within 1 month prior to screening;
  13. With a history of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, 25 mL of spirit, or 100 mL of wine), or positive for alcohol breath test;
  14. With a history of substance abuse or drug abuse, or positive for drug screen;
  15. Positive for tobacco screen;
  16. With significant changes in physical activity within 6 months prior to screening, or not agree to abstain from strenuous physical exercise during the trial;
  17. Positive for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or treponema pallidum antibody (TPPA);
  18. Abnormal serum calcium level (beyond the laboratory reference range) during the screening;
  19. Ear temperature > 37.5 °C during the screening period; and/or sitting systolic blood pressure (SBP) > 140 mmHg or \< 90 mmHg, and/or diastolic blood pressure (DBP) > 90 mmHg or \< 50 mmHg; and/or pulse rate > 100 beats/min or \< 50 beats/min during the screening.
  20. Clinically significant abnormal or > 450 ms during screening, or with a prior history of clinically significant abnormal ECG;
  21. Unwilling to take adequate measures during the study.
  22. Subjects who, in the opinion of the investigators, are not eligible to participate in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Part I: HLX14 group

    Part I: HLX14 are given subcutaneous injection at a single dose of 60 mg.

    Drug: HLX14

  • Active comparator
    Part I: EU-Prolia® group

    Part I: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.

    Drug: EU-Prolia®

  • Experimental
    Part II: HLX14 group

    Part II: HLX14 are given subcutaneous injection at a single dose of 60 mg.

    Drug: HLX14

  • Active comparator
    Part II: EU-Prolia® group

    Part II: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.

    Drug: EU-Prolia®

  • Active comparator
    Part II: US-Prolia® group

    Part II: US-Prolia® are given subcutaneous injection at a single dose of 60 mg.

    Drug: US-Prolia®

  • Active comparator
    Part II: CN-Prolia® group

    Part II: CN-Prolia® are given subcutaneous injection at a single dose of 60 mg.

    Drug: CN-Prolia®

Interventions

  • DrugHLX14

    healthy volunteers receive HLX14 (60mg) once

  • healthy volunteers receive EU-Prolia® (60mg) once

  • DrugUS-Prolia®

    healthy volunteers receive US-Prolia® (60mg) once

  • DrugCN-Prolia®

    healthy volunteers receive CN-Prolia® (60mg) once

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    Area under the serum concentration-time curve from time 0 to the last concentration-quantifiable time t of denosumab

    Time frame: from 0 to day 274

  2. Cmax

    Maximum serum concentration following administration of denosumab

    Time frame: from 0 to day 274

  3. AUC0-inf

    Area under the serum concentration-time curve from time 0 to infinity

    Time frame: from 0 to day 274

Secondary outcomes

  1. Tmax

    Time to reach maximum serum concentration following administration

    Time frame: from 0 to day 274

  2. CL/F

    Total clearance

    Time frame: from 0 to day 274

  3. λz

    Apparent terminal elimination rate constant

    Time frame: from 0 to day 274

  4. t1/2

    Elimination half life

    Time frame: from 0 to day 274

  5. Vd/F

    Apparent volume of distribution

    Time frame: from 0 to day 274

  6. %AUCex

    Area extrapolated from time to infinity as a percentage of total AUC0-inf

    Time frame: from 0 to day 274

  7. MRT

    Mean residence time

    Time frame: from 0 to day 274

  8. AUC0-28d and AUC0-112d

    Area under the drug concentration-time curve from day 0 to day 28 (4 weeks) and from day 0 to day 112 (16 weeks)

    Time frame: from 0 to day 112

  9. AUEC0-t

    Area under the effect-time curve from time zero to last time of quantifiable concentration of serum CTX1

    Time frame: from 0 to day 274

  10. Imin

    Minimum observed concentration of serum CTX1

    Time frame: from 0 to day 274

  11. Imax

    Maximum percent inhibition of serum CTX1

    Time frame: from 0 to day 274

  12. Tmin

    Time to reach Imin of serum CTX1

    Time frame: from 0 to day 274

Other outcomes

  1. AEs and SAEs

    Adverse events and serious adverse events

    Time frame: from 0 to day 274

  2. Physical examination

    Time frame: from 0 to day 274

  3. Vital signs

    Time frame: from 0 to day 274

  4. Injection site reactions

    Time frame: from 0 to day 274

  5. Laboratory tests (haematology, serum chemistry, and urinalysis)

    Time frame: from 0 to day 274

  6. 12-lead ECG

    Time frame: from 0 to day 274

  7. ADA and NAb

    Positive rate of anti-drug antibody, including neutralising antibody

    Time frame: from 0 to day 274

07

Study locations

1 site
  • Huashan Hospital,Fudan University
    Shanghai, Shanghai 200040, China
08

References and documents

Publications

  • Li N, Chu N, Zhu L, Wu X, Wei Q, Wang J, Hu X, Yu H, Wang Q, Yuan W, Huang K, Zhang J. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study. Clin Transl Sci. 2024 Dec;17(12):e70089. doi: 10.1111/cts.70089. PubMed 39700054 ↗
  • American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 2022 Mar;111 Suppl 1:S5-S80. doi: 10.1002/cpt.2521. No abstract available. Erratum In: Clin Pharmacol Ther. 2022 Apr 17:1344. doi: 10.1002/cpt.2599. PubMed 35132630 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Sep 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 1, 2020
StartActual
Nov 3, 2020
Primary completionActual
Sep 12, 2023
CompletionActual
Sep 12, 2023
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04534582
Responsible party
Sponsor
First posted
Sep 1, 2020
Start date
Nov 3, 2020
Primary completion
Sep 12, 2023
Completion
Sep 12, 2023
Last update
Jan 20, 2025

Study contacts

Jing Zhang, Doctor
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion